Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Subscribe To Our Newsletter & Stay Updated
